Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes (NCT06415214) | Clinical Trial Compass
CompletedPhase 2
Efficacy and Safety of HRS-7535 Tablets in Adults With Diabetic Kidney Disease in Type 2 Diabetes
China281 participantsStarted 2024-06-21
Plain-language summary
The study is a 16-week multicenter, randomized, double-blind, placebo-controlled, parallel-designed Phase II clinical study. The aim of this trial is to evaluate the efficacy and safety of HRS-7535 in subjects with diabetic kidney disease in type 2 diabetes.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female subjects, 18-75 years of age at the time of signing informed consent;
✓. Body weight ≥50 kg, 20.0 kg/m2 ≤BMI ≤40.0 kg/m2;
✓. Diabetic kidney disease was diagnosed, and the eGFR≥30 mL/min/1.73 m2;
✓. Had a history of T2DM at least 3 months, or had diabetic retinopathy as assessed by the investigators;
✓. UACR ≥300 and \<3000 mg/g;
✓. HbA1c ≥6.5% and ≤10.0%;
✓. ACEI/ARB was used for ≥3 months and ACEI/ARB was stabilized at either the maximum recommended dose (reference to the drug label) or the maximum tolerated dose within 4 weeks;
✓. Use hypoglycemic drugs for ≥3 months (the dosage of SGLT2i remains stable if used);
Exclusion criteria
✕. Have type 1 diabetes mellitus or specific type of diabetes;
✕. Acute kidney injury or dialysis treatment within 6 months;
✕. Kidney transplantation is planned during the trial;
✕. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening;
✕. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix;
✕. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;
✕. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method;